Resveratrol triggers the pro-apoptotic endoplasmic reticulum stress response and represses pro-survival xbp1 signaling in human multiple myeloma cells

Experimental Hematology

Volumn 39, Issue 10, 2011, Pages 999-1006

  Wang, Feng Ming ^a,b   Galson, Deborah L ^a,c   Roodman, G David ^a,c   Ouyang, Hongjiao ^a,d  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b SICHUAN UNIVERSITY   (China)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INOSITOL REQUIRING ENZYME 1ALPHA; MESSENGER RNA; RESVERATROL; RIBONUCLEASE; SIRTUIN 1; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; X BOX BINDING PROTEIN 1;

APOPTOSIS; ARTICLE; BINDING SITE; CELL SURVIVAL; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG TARGETING; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE; GENE ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; MOLECULAR BIOLOGY; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DNA BINDING; PROTEIN PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SPLICING; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; WESTERN BLOTTING; XBP1 GENE;

APOPTOSIS; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; DNA, NEOPLASM; DNA-BINDING PROTEINS; DRUG SCREENING ASSAYS, ANTITUMOR; ENDOPLASMIC RETICULUM; ENDORIBONUCLEASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MULTIPLE MYELOMA; NEOPLASM PROTEINS; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN-SERINE-THREONINE KINASES; RNA SPLICING; SIGNAL TRANSDUCTION; SIRTUIN 1; STILBENES; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; UNFOLDED PROTEIN RESPONSE;

EID: 80052827034     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2011.06.007     Document Type: Article

References (33)

1. Raab M.S., Podar K., Breitkreutz I., Richardson P.G., Anderson K.C. Multiple myeloma. Lancet 2009, 374:324-339.
2. Todd D.J., Lee A.H., Glimcher L.H. The endoplasmic reticulum stress response in immunity and autoimmunity. Nat Rev Immunol 2008, 8:663-674.
3. Lee A.H., Iwakoshi N.N., Anderson K.C., Glimcher L.H. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci U S A 2003, 100:9946-9951.
4. Obeng E.A., Carlson L.M., Gutman D.M., Harrington W.J., Lee K.P., Boise L.H. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006, 107:4907-4916.
5. Papandreou I., Denko N.C., Olson M., et al. Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma. Blood 2011, 117:1311-1314.
6. Lin J.H., Walter P., Yen T.S. Endoplasmic reticulum stress in disease pathogenesis. Annu Rev Pathol 2008, 3:399-425.
7. Ron D., Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 2007, 8:519-529.
8. Yoshida H., Matsui T., Yamamoto A., Okada T., Mori K. XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell 2001, 107:881-891.
9. Lin J.H., Li H., Yasumura D., et al. IRE1 signaling affects cell fate during the unfolded protein response. Science 2007, 318:944-949.
10. Yoshida H., Oku M., Suzuki M., Mori K. pXBP1(U) encoded in XBP1 pre-mRNA negatively regulates unfolded protein response activator pXBP1(S) in mammalian ER stress response. J Cell Biol 2006, 172:565-575.
11. Carrasco D.R., Sukhdeo K., Protopopova M., et al. The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell 2007, 11:349-360.
12. Iwakoshi N.N., Lee A.H., Vallabhajosyula P., Otipoby K.L., Rajewsky K., Glimcher L.H. Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1. Nat Immunol 2003, 4:321-329.
13. Bagratuni T., Wu P., Gonzalez de Castro D., et al. XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments. Blood 2010, 116:250-253.
14. Urano F., Wang X., Bertolotti A., et al. Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. Science 2000, 287:664-666.
15. Baur J.A., Sinclair D.A. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006, 5:493-506.
16. Khan N., Afaq F., Mukhtar H. Cancer chemoprevention through dietary antioxidants: progress and promise. Antioxid Redox Signal 2008, 10:475-510.
17. Sun C., Hu Y., Liu X., et al. Resveratrol downregulates the constitutional activation of nuclear factor-kappaB in multiple myeloma cells, leading to suppression of proliferation and invasion, arrest of cell cycle, and induction of apoptosis. Cancer Genet Cytogenet 2006, 165:9-19.
18. Boissy P., Andersen T.L., Abdallah B.M., Kassem M., Plesner T., Delaisse J.M. Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation. Cancer Res 2005, 65:9943-9952.
19. Bhardwaj A., Sethi G., Vadhan-Raj S., et al. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood 2007, 109:2293-2302.
20. Reis-Sobreiro M., Gajate C., Mollinedo F. Involvement of mitochondria and recruitment of Fas/CD95 signaling in lipid rafts in resveratrol-mediated antimyeloma and antileukemia actions. Oncogene 2009, 28:3221-3234.
21. Shajahan A.N., Riggins R.B., Clarke R. The role of X-box binding protein-1 in tumorigenicity. Drug News Perspect 2009, 22:241-246.
22. Herranz D., Serrano M. SIRT1: recent lessons from mouse models. Nat Rev Cancer 2010, 10:819-823.
23. Wang F.M., Chen Y.J., Ouyang H.J. Regulation of unfolded protein response modulator XBP1s by acetylation and deacetylation. Biochem J 2010, 433:245-252.
24. Merksamer P.I., Papa F.R. The UPR and cell fate at a glance. J Cell Sci 2010, 123:1003-1006.
25. Davenport E.L., Moore H.E., Dunlop A.S., et al. Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells. Blood 2007, 110:2641-2649.
26. Pereira E.R., Liao N., Neale G.A., Hendershot L.M. Transcriptional and post-transcriptional regulation of proangiogenic factors by the unfolded protein response. PLoS One 2010, 5:e12521.
27. Kakiuchi C., Iwamoto K., Ishiwata M., et al. Impaired feedback regulation of XBP1 as a genetic risk factor for bipolar disorder. Nat Genet 2003, 35:171-175.
28. Lee A.H., Iwakoshi N.N., Glimcher L.H. XBP-1 regulates a subset of endoplasmic reticulum resident chaperone genes in the unfolded protein response. Mol Cell Biol 2003, 23:7448-7459.
29. Jazirehi A.R., Bonavida B. Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther 2004, 3:71-84.
30. Woo K.J., Lee T.J., Lee S.H., et al. Elevated gadd153/chop expression during resveratrol-induced apoptosis in human colon cancer cells. Biochem Pharmacol 2007, 73:68-76.
31. Chauhan D., Li G., Hideshima T., et al. JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cells. J Biol Chem 2003, 278:17593-17596.
32. Gupta S., Deepti A., Deegan S., Lisbona F., Hetz C., Samali A. HSP72 protects cells from ER stress-induced apoptosis via enhancement of IRE1alpha-XBP1 signaling through a physical interaction. PLoS Biol 2010, 8:e1000410.
33. Chauhan D., Bandi M., Singh A.V., et al. A novel SIRT1 activator SIRT1720 triggers in vitro and in vivo cytotoxicity in multiple myeloma via ATM-dependent mechanism. Blood 2010, 116. Abstact 3007.